Akeso Biopharma Inc (Akesobio, HKEX code: 9926.HK) was officially listed on the Main Board of the Hong Kong Exchanges and Clearing Market (HKEX) on April 24, becoming the first innovative pharmaceutical company in Zhongshan city to land on the capital market. 

It is reported that the issue price of Akesobio has an upper limit of HK$16.18, with a financing volume of more than US$300 million. 

In March 2012, Dr Xia Yu and other overseas returnees with doctoral degrees established Akesobio at the National Health Technology Park in Zhongshan's Torch Development Zone. For eight years, Akesobio has adopted Zhongshan as its research and development headquarters and set up subsidiaries in such places as the United States, Australia as well as Beijing, Shanghai and Guangzhou. 

Akesobio has so far developed more than 20 new antibody product lines, covering a variety of medical fields such as tumors, autoimmune diseases, cardiovascular diseases, inflammation, metabolic diseases, pain, and etc. Its international standard production base at the Zhongshan headquarters has successfully produced macromolecular products in 9 clinical stages and has established important partnerships with leading domestic and global pharmaceutical companies.